Management of Patients with Microhematuria: AUA/SUFU guidelines
Recent guidelines regarding the treatment of adult patients with suspected or confirmed cases of Microhematuria were released by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & urogenital reconstruction (SUFU) and were published in JAMA.
The prevalence of microhematuria among healthy patients ranges from 2.4% to 31.1%.1 Although 13.1% of gross hematuria episodes are associated with malignancy, only 0.3% to 6.3% of microhematuria episodes are associated with malignancy.
Characteristics of guidelines score:
The AUA and SUFU developed this guideline with representation from the American College of Obstetricians and Gynaecologists and a patient advocate.
Panellists disclosed conflicts of interest and were disqualified if conflicts compromised objectivity.
Some major recommendations of the latest guidelines were:
Microhematuria should be considered to be more than 3 blood cells per high power field on microscopic evaluation of a urine specimen.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.